Merus N.V.
MRUSDrugs in Pipeline
5
Phase 3 Programs
2
Upcoming Catalysts
0
Next Catalyst
None scheduled
Market Overview
Stock performance and key metrics
0 upcoming, 0 past
No catalysts found.
Petosemtamab
Head and Neck Squamous Cell Carcinoma
Investigator's Choice
Head and Neck Squamous Cell Carcinoma
MCLA-158
Advanced/Metastatic Solid Tumors
Zenocutuzumab
Breast Cancer Metastatic
MCLA-129
Non-Small Cell Lung Cancer Metastatic
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Petosemtamab | Phase 3 | Head and Neck Squamous Cell Carcinoma | - | - |
Investigator's Choice | Phase 3 | Head and Neck Squamous Cell Carcinoma | - | - |
MCLA-158 | Phase 2 | Advanced/Metastatic Solid Tumors | - | - |
Zenocutuzumab | Phase 2 | Breast Cancer Metastatic | - | - |
MCLA-129 | Phase 2 | Non-Small Cell Lung Cancer Metastatic | - | - |
Head and Neck Squamous Cell Carcinoma
2 drugs in this indication
Breast Cancer Metastatic
1 drug in this indication
Advanced/Metastatic Solid Tumors
1 drug in this indication
Non-Small Cell Lung Cancer Metastatic
1 drug in this indication
Source: CatalystAlert database (ClinicalTrials.gov, SEC EDGAR)
Frequently asked questions
What is in Merus N.V.'s drug pipeline?→
CatalystAlert tracks 5 drug candidates in Merus N.V.'s (MRUS) pipeline across Phase 3, Phase 2. Its lead program is Petosemtamab (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Merus N.V.'s next FDA catalyst?→
CatalystAlert tracks every upcoming catalyst for Merus N.V. (MRUS) — PDUFA decision dates, Phase 1/2/3 trial readouts, FDA advisory committee meetings and NDA/BLA filings — each confidence-rated as confirmed, estimated or AI-detected.
How do I track MRUS biotech catalysts?→
Add MRUS to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Merus N.V.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.